Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
NCT ID: NCT00563524
Last Updated: 2024-08-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
76 participants
INTERVENTIONAL
2007-12-20
2010-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.
NCT00417820
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
NCT06643260
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
NCT03210961
Study in Patients With Mild to Moderate Psoriasis
NCT01451346
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
NCT02969018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ILV-094
SC and IV administration on days 1, 14, 28, and 42
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ILV-094
SC and IV administration on days 1, 14, 28, and 42
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physician Area and Severity Index (PASI) greater than 11.
* Physician Global Assessment (PGA) greater than 3.
Exclusion Criteria
* Live vaccines within 3 months before test article administration or during the study.
* Use of any biologic therapy within approximately 5 half-lives before test article administration. Approximate half-lives of biologic therapies approved for psoriasis are as follows: Enbrel, 5 days; Humira, 14 days; Remicade, 9 days; Amevive, 12 days; Raptiva, 6 days. It is recommended that Amevive be discontinued for at least 90 days because of its long clinical duration of action.
* Psoralen plus ultraviolet A radiation (PUVA) therapy within 4 weeks before study day 1.
* Ultraviolet B (UVB) therapy within 2 weeks before study day 1.
* Receipt of systemic psoriasis therapy (eg, oral retinoids, methotrexate, hydroxyurea, cyclosporine, or azathioprine) or systemic corticosteroids within 4 weeks before study day 1.
* Topical steroids, topical vitamin A or D analog preparations, or anthralin within 2 weeks before study day 1. (Exception: topical therapies, including steroids at no higher than mild strength \[class 6 or 7 topical corticosteroids\], are permitted on the scalp, axillae, face, and groin, but the dose of the medication must be kept stable throughout the trial.)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
David Stoll, MD
Beverly Hills, California, United States
Dermatology Research
Santa Monica, California, United States
Miami Research Associates
South Miami, Florida, United States
MRA Clinical Research
South Miami, Florida, United States
Hudson Dermatology
Evansville, Indiana, United States
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana, United States
Dawes Fretzin Dermatology Group
Indianapolis, Indiana, United States
Hamzavi Dermatology
Fort Gratiot, Michigan, United States
Central Dermatology
St Louis, Missouri, United States
New York University Medical Center
New York, New York, United States
Mount Sinai School of Medicine
New York, New York, United States
Duke Clinical Reseach Unit
Durham, North Carolina, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Baylor Research Institute
Dallas, Texas, United States
Stratical Medical
Edmonton, Alberta, Canada
University of Alberta, Hospital Site Clinical Sciences Building
Edmonton, Alberta, Canada
The Northern Alberta Clinical Trials and Research Centre (NACTRC)
Edmonton, Alberta, Canada
Bio Pharma Services Inc
Toronto, Ontario, Canada
K. Papp Clinical Research
Waterloo, Ontario, Canada
Innovaderm Recherches Inc
Montreal, Quebec, Canada
Queen Mary Hospital
Hong Kong, , Hong Kong
FARMOVS Parexel (Pty) Ltd
Bloemfontein, Free State, South Africa
Parexel George
George, Western Cape, South Africa
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1981002
Identifier Type: OTHER
Identifier Source: secondary_id
2009-012554-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3199K2-1105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.